Gastrointestinal Bleeding in Patients Receiving a Combination of Aspirin, Clopidogrel, and Enoxaparin in Acute Coronary Syndrome
Authors:
- Siu-Yin WongSWSiu-Yin Wong
- Kwok-Fai LamKLKwok-Fai Lam
- Chee-My ChangCCChee-My Chang
- Yuk-Kong LauYLYuk-Kong Lau
- Wai-Ming ChuWCWai-Ming Chu
- Benjamin C.Y. WongBWBenjamin C.Y. Wong
- 1 April 2008
- journal article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 103 (4) , 865-871
Abstract
Incidence of upper gastrointestinal bleeding in a real-life situation. The effect of proton pump inhibitor (PPI) treatment was also analyzed. METHOD From January 2002 to December 2006, all patients receiving combination therapy were analyzed. The end point was the occurrence of upper gastrointestinal bleeding during combination therapy or within 7 days of stopping enoxaparin. RESULTS The patient group consisted of 666 patients (age 72.1 ± 12.6 yr). Gastrointestinal bleeding occurred in 18 (2.7%) patients. The overall hospital mortality was 4.1% (27 patients). A cardiac event was the major cause (N = 24, 3.6%). Only one patient died of massive gastrointestinal bleeding (0.15%). Multiple logistic regression analysis demonstrated that previous peptic ulcer, cardiogenic shock, and the lack of PPI coprescription were significant risk factors for gastrointestinal bleeding. The age-adjusted odds ratio (95% confidence interval) for gastrointestinal bleeding was 5.07 (1.31–16.58) for previous peptic ulcer, 21.41 (2.56–146.68) for cardiogenic shock, and 0.068 (0.010–0.272) for the coprescription with a PPI. CONCLUSION In real life, the incidence of gastrointestinal bleeding associated with the combination of aspirin, clopidogrel, and enoxaparin therapy was estimated to be 2.7%. Previous peptic ulcer disease or cardiogenic shock were significant independent risk factors. Coprescription with a PPI can significantly reduce the risk....Keywords
This publication has 17 references indexed in Scilit:
- Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary SyndromesCirculation, 2006
- Upper gastrointestinal bleeding associated with antiplatelet drugsAlimentary Pharmacology & Therapeutics, 2005
- High incidence of clopidogrel‐associated gastrointestinal bleeding in patients with previous peptic ulcer diseaseAlimentary Pharmacology & Therapeutics, 2003
- ACC/AHA 2002 guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction—summary articleJACC, 2002
- Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment ElevationNew England Journal of Medicine, 2001
- Nitrovasodilators, Low-Dose Aspirin, Other Nonsteroidal Antiinflammatory Drugs, and the Risk of Upper Gastrointestinal BleedingNew England Journal of Medicine, 2000
- Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classificationGut, 1999
- Effect of ranitidine gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugsDigestive Diseases and Sciences, 1989
- Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine.BMJ, 1988
- Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinaseJACC, 1988